Large pharma companies reduced headcounts by more than 22K in 2025 as $300B patent cliff looms

headcount, reduction, revenue per employee

Large pharmaceutical companies, each with at least $20 billion in 2025 revenue, collectively reduced their workforces by more than 22,000 employees last year.  Among the 17 largest pharma companies analyzed in a Fierce Pharma review of annual reports, only five logged a head count increase in 2025…

Mar 23^rd • 10 mins read

Hiring Managers: What Should You Do During a Hiring Freeze?

careers

As we begin 2023, many companies are experiencing hiring freezes. Some hiring managers have a sense of how long the freeze will be, some don’t, but all know that it’s temporary. So, what can hiring managers do during the freeze to stay competitive in the war for talent? Hiring is a competition…

Jan 26^th • 5 mins read

Transforming oncology: Five frontiers driving progress in cancer care

Thought Leadership, Oncology

From biomarker-driven breakthroughs to AI-powered early detection and a renewed commitment to equity and patient centricity, the past 12 months have seen major strides across cancer research, treatment, and communication. At Inizio, we’ve had a front-row seat to this transformation, supporting…

May 16^th • 5 mins read

Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?

antibody, antibody-drug conjugates, ADC's, FDA

ADCs (Antibody-Drug Conjugates) are a promising area in oncology drug development, improving the therapeutic window of potent, nonspecific payloads by conjugating them to antibodies. The FDA has approved nine ADCs for solid and hematological tumors, with several more showing promising clinical ac…

Apr 26^th • 15 mins read